ANTI-NEPRILYSIN MARKET ANALYSIS

Market Challenges And Opportunities

Restaints

Issues:
• Side-effects of Anti-Neprilysin Drugs
• Product Recalls

Global Anti-Neprilysin Market - Key Players

Major players operating in the global anti-neprilysin market include BIOPROJET, Novartis AG, Pharmaleads SA, Theravance Biopharm, Cipla Inc, and Oceanic Pharmachem Pvt. Ltd.

Global Anti-Neprilysin Market : Key Developments

In December 2020, The U.S. Food and Drug Administration, the central drug regulatory authority in the U.S., announced that an expanded indication was warranted for sacubitril/valsartan that allow it as a treatment for certain patients with HF with preserved ejection fraction

In March 2021, Stragen Pharma SA, a Switzerland-based biopharmaceutical company, started enrollment of healthy volunteers in a phase II trial of STR-324 for postoperative pain. STR-324 is an anti-nephrilysin investigational new drug (IND) candidate. .

On January 18, 2023, Cipla Inc., a India-based biopharmaceutical and medical company, announced the launch of Cippoint, a point-of-care testing device. The device offers a wide range of testing parameters including cardiac markers, diabetes, infectious diseases, fertility, thyroid function, inflammation, metabolic markers, and coagulation markers. The device had been approved in August 2020, by the European In-Vitro Diagnostic Device (IVD) Directive, thus ensuring reliable testing solutions. The IVD sets out the essential safety, health, design, and manufacturing requirements that in vitro diagnostic medical devices and their accessories must meet. This ensures universally high safety standards, providing public confidence in the system. It enables the products to be used in any European Union country.

Global Anti-Neprilysin Market: Restraint

Side-effects of Anti-Neprilysin Drugs

The side effects of anti-neprilysin drugs can restrain growth of the global anti-neprilysin market. Sacubitril/valsartan was associated with a higher incidence of hypotension, symptomatic hypotension and angioedema .

This restrain can be overcome by the taking the right dose of the drug, as recommended by the physician.

Product Recalls

Manufacturing, production, and design flaws in anti-nepriysin drugs can restrain the growth of the market. In August 2020, the U.S. Food and Drug Administration (FDA) announced the product recall of valsartan tablets manufactured by Hetero Labs Ltd., aIndia-based biopharmaceutical company, for containing a probable cancer-causing chemical.

This can be overcome by strict compliance with regulatory guidelines and the adoption of good manufacturing practices.